bioMerieux Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$18.6M
Doctors Paid
2,203
Transactions
4,443
2024 Total
$1.7M
Payment Breakdown by Category
Research$16.3M (88.0%)
Consulting$292,613 (1.6%)
Travel$278,994 (1.5%)
Food & Beverage$73,862 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.3M | 1,097 | 88.0% |
| Debt forgiveness | $472,360 | 12 | 2.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $383,854 | 133 | 2.1% |
| Gift | $341,549 | 41 | 1.8% |
| Honoraria | $331,554 | 161 | 1.8% |
| Consulting Fee | $292,613 | 319 | 1.6% |
| Travel and Lodging | $278,994 | 228 | 1.5% |
| Food and Beverage | $73,862 | 2,436 | 0.4% |
| Education | $23,000 | 1 | 0.1% |
| Long term medical supply or device loan | $16,076 | 7 | 0.1% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $13,885 | 7 | 0.1% |
| Grant | $10,000 | 1 | 0.1% |
Payments by Type
Research
$16.3M
1,097 transactions
General
$2.2M
3,346 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| GN22 | $1.5M | 0 | 3 |
| VIDAS TBI | $1.3M | 0 | 19 |
| GP21 | $1.0M | 0 | 24 |
| GP20 | $1.0M | 0 | 2 |
| Vidas TBI | $943,500 | 0 | 2 |
| GN23 | $660,767 | 0 | 1 |
| SEPSIGN: Early Identification of SEPsis SIGNSs in Emergency Department | $630,678 | 0 | 15 |
| ETEST Tebipenem (TBP) | $610,126 | 0 | 8 |
| AFO4 | $561,599 | 0 | 22 |
| SpotFire STI/V Pilot Study | $432,087 | 0 | 42 |
| BioFire PN1.x Prospective Study | $377,432 | 0 | 85 |
| Feasibility of a Rapid Molecular Diagnostic of Gut Microbiome Dysbiosis to Predict Individual Risk of Clostridioides difficile Colonization and/or Infection Using the BioFire System | $337,496 | 0 | 6 |
| CTR 1000/2126164 | $260,150 | 0 | 6 |
| ETEST DFX | $243,358 | 0 | 2 |
| AF04 | $240,206 | 0 | 1 |
| VITEK REVEAL Gram-Negative Isolate Assay | $230,027 | 0 | 23 |
| VIDAS TB IGRA NILOR Study | $229,195 | 0 | 30 |
| SEPSIGN Early identification of SEPsis SIGN in emergency department | $229,067 | 0 | 9 |
| VIDAS NephroClear CCL 14 | $182,544 | 0 | 12 |
| NILOR Study | $156,246 | 0 | 9 |
| VITEK REVEAL EEP | $147,523 | 0 | 9 |
| VITEK 2 and VITEK 2 Compact SS04 Antimicrobial Susceptibility Tests | $146,506 | 0 | 37 |
| VITEK 2 GP19 | $144,452 | 0 | 5 |
| Feasibility of Using a Prototype BioFire HR B/V Blood Test to Discriminate Etiologies of LRTI in a Sri Lankan Population | $138,000 | 0 | 3 |
| BTA MPI | $137,351 | 0 | 4 |
| VIDAS PCT | $136,905 | 0 | 4 |
| E0443 - EPISEQ_USA_VUMC_HUMPHRIES_IIR_2021 | $112,855 | 0 | 4 |
| SpotFire R/ST Prospective Study | $112,050 | 0 | 16 |
| Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | $107,783 | 1 | 17 |
| Gram-negative Growth and Time to Detection | $104,510 | 0 | 8 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Rodrigo Hasbun, M.d., M.p.h, M.D., M.P.H | Infectious Disease | Houston, TX | $11,653 | $0 |
| Dr. Michael Kobernick, Md, MD | Emergency Medicine | Warren, MI | $11,446 | $0 |
| Edward Septimus, Md, MD | Infectious Disease | Houston, TX | $11,374 | $0 |
| Jason Wilson, Md, MD | Emergency Medicine | Tampa, FL | $11,177 | $0 |
| Girish Putcha, Md, Phd, MD, PHD | Molecular Genetic Pathology | Stanford, CA | $10,928 | $0 |
| Dr. Jeffrey Bazarian, M.d, M.D | Emergency Medicine | Rochester, NY | $10,902 | $0 |
| Dr. Rosemary She, Md, MD | Anatomic Pathology & Clinical Pathology | Duarte, CA | $10,373 | $0 |
| Steven Conrad, M.d, M.D | Emergency Medicine | Shreveport, LA | $9,888 | $0 |
| Daniel Engelman, M.d, M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Springfield, MA | $9,462 | $0 |
| James Miner | Emergency Medicine | Minneapolis, MN | $9,441 | $0 |
| Estela Odaniell, M.d, M.D | Pediatric Emergency Medicine | Corpus Christi, TX | $9,440 | $0 |
| Stephen Pastores, Md, MD | Critical Care Medicine | New York, NY | $9,105 | $0 |
| Jill Hagenkord, M.d, M.D | Anatomic Pathology & Clinical Pathology | Omaha, NE | $9,085 | $0 |
| Charles Cairns | Emergency Medicine | Durham, NC | $8,920 | $0 |
| Mr. David Gilbert, Md, MD | Infectious Disease | Portland, OR | $8,501 | $0 |
| Gyorgy Frendl, Md Phd, MD PHD | Anesthesiology | Boston, MA | $8,498 | $0 |
| Owen Albin, Md, MD | Internal Medicine | Ann Arbor, MI | $7,830 | $0 |
| Bradley Connor, Md, MD | Gastroenterology | New York, NY | $7,745 | $0 |
| Dr. Alexander Sah, Md, MD | Adult Reconstructive Orthopaedic Surgery | Fremont, CA | $7,079 | $0 |
| Nicole Hubbard, Md, MD | Clinical Pathology | Toledo, OH | $6,761 | $0 |
| Ms. Virginia Calega, Md, MD | Internal Medicine | Camp Hill, PA | $6,700 | $0 |
| Dr. Glenn Harnett, Md, MD | Emergency Medicine | Hoover, AL | $6,606 | $0 |
| Stephen Haire, Md, MD | Emergency Medicine | Clearwater, FL | $5,955 | $0 |
| Anthony Dempsey, M.d, M.D | Critical Care Medicine | Pikeville, KY | $5,936 | $0 |
| Dr. Zoe Weiss, M.d, M.D | Internal Medicine | Boston, MA | $5,889 | $0 |
Ad
Top Products
- VITEK2 $3.3M
- VITEK 2 $2.0M
Associated Products (30)
- VITEK2 $3.3M
- VITEK 2 $2.0M
- VIDAS $790,659
- VITEK $581,158
- ETEST $360,251
- VIDAS BRAHMS PCT $193,540
- BacTAlert $137,351
- VIDAS PCT $127,312
- VIDAS 3 $108,103
- BacT/Alert $93,737
- NEPROCHECK $82,339
- bacT/ALERT $78,022
- Vidas Brahms PCT $76,829
- ETEST Aztreonam (AT) $67,275
- Etest $52,218
- Etest IPR and MEV $41,294
- FILMARRAY GASTROINTESTINAL (GI) PANEL $38,538
- Vitek 2 $36,139
- VIDAS TBI (GFAP, UCH-L1) $34,587
- VIDAS3 $34,031
- NEPHROCHECK LIQUID CONTROL KIT $33,788
- chromID $33,560
- VIDAS NEPHROCHECK $25,902
- bactT/ALERT Virtuo $23,700
- Virtuo $20,790
- MASS SPEC $18,014
- VIDAS PCT kits $17,338
- miniVIDAS $16,865
- VIRTUO $15,779
- BIOFIRE BLOOD CULTURE IDENTIFICATION 2 (BCID2) PANEL $10,925
Payment Categories
- Food & Beverage $73,862
- Consulting $292,613
- Travel & Lodging $278,994
- Research $16.3M
About bioMerieux Inc
bioMerieux Inc has made $18.6M in payments to 2,203 healthcare providers, recorded across 4,443 transactions in the CMS Open Payments database. In 2024, the company paid $1.7M. The top product by payment volume is VITEK2 ($3.3M).
Payments were distributed across 112 medical specialties. The top specialty by payment amount is Critical Care Medicine ($490,109 to 95 doctors).
Payment categories include: Food & Beverage ($73,862), Consulting ($292,613), Research ($16.3M), Travel & Lodging ($278,994).
bioMerieux Inc is associated with 30 products in the CMS Open Payments database, including VITEK2, VITEK 2, and VIDAS.